Global Targeted Drug VEGF Inhibitors for NSCLC Market Growth (Status and Outlook) 2025-2031
According to this study, the global Targeted Drug VEGF Inhibitors for NSCLC market size will reach US$ million by 2031.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Targeted Drug VEGF Inhibitors for NSCLC Industry Forecast” looks at past sales and reviews total world Targeted Drug VEGF Inhibitors for NSCLC sales in 2024, providing a comprehensive analysis by region and market sector of projected Targeted Drug VEGF Inhibitors for NSCLC sales for 2025 through 2031. With Targeted Drug VEGF Inhibitors for NSCLC sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Drug VEGF Inhibitors for NSCLC industry.
This Insight Report provides a comprehensive analysis of the global Targeted Drug VEGF Inhibitors for NSCLC landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted Drug VEGF Inhibitors for NSCLC portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Drug VEGF Inhibitors for NSCLC market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Drug VEGF Inhibitors for NSCLC and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Drug VEGF Inhibitors for NSCLC.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Drug VEGF Inhibitors for NSCLC market by product type, application, key players and key regions and countries.
Segmentation by Type:
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Targeted Drug VEGF Inhibitors for NSCLC Industry Forecast” looks at past sales and reviews total world Targeted Drug VEGF Inhibitors for NSCLC sales in 2024, providing a comprehensive analysis by region and market sector of projected Targeted Drug VEGF Inhibitors for NSCLC sales for 2025 through 2031. With Targeted Drug VEGF Inhibitors for NSCLC sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Drug VEGF Inhibitors for NSCLC industry.
This Insight Report provides a comprehensive analysis of the global Targeted Drug VEGF Inhibitors for NSCLC landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted Drug VEGF Inhibitors for NSCLC portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Drug VEGF Inhibitors for NSCLC market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Drug VEGF Inhibitors for NSCLC and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Drug VEGF Inhibitors for NSCLC.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Drug VEGF Inhibitors for NSCLC market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Bevacizumab
- Others
- Squamous Cell Carcinoma of NSCLC
- Adenocarcinoma of NSCLC
- Large Cell Carcinoma of NSCLC
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Roche
- Pfizer
- Allergan
- Amgen
- Biocon
- Reliance Lifesciences
- Beaconpharma
- Celgene Corporation
- Fujifilm Kyowa Kirin Biologics
- Hetero Drugs
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size (2020-2031)
2.1.2 Targeted Drug VEGF Inhibitors for NSCLC Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Targeted Drug VEGF Inhibitors for NSCLC by Country/Region (2020, 2024 & 2031)
2.2 Targeted Drug VEGF Inhibitors for NSCLC Segment by Type
2.2.1 Bevacizumab
2.2.2 Others
2.3 Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type
2.3.1 Targeted Drug VEGF Inhibitors for NSCLC Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
2.4 Targeted Drug VEGF Inhibitors for NSCLC Segment by Application
2.4.1 Squamous Cell Carcinoma of NSCLC
2.4.2 Adenocarcinoma of NSCLC
2.4.3 Large Cell Carcinoma of NSCLC
2.5 Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application
2.5.1 Targeted Drug VEGF Inhibitors for NSCLC Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
3 TARGETED DRUG VEGF INHIBITORS FOR NSCLC MARKET SIZE BY PLAYER
3.1 Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Player
3.1.1 Global Targeted Drug VEGF Inhibitors for NSCLC Revenue by Player (2020-2025)
3.1.2 Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Player (2020-2025)
3.2 Global Targeted Drug VEGF Inhibitors for NSCLC Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 TARGETED DRUG VEGF INHIBITORS FOR NSCLC BY REGION
4.1 Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region (2020-2025)
4.2 Global Targeted Drug VEGF Inhibitors for NSCLC Annual Revenue by Country/Region (2020-2025)
4.3 Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth (2020-2025)
4.4 APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth (2020-2025)
4.5 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth (2020-2025)
4.6 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth (2020-2025)
5 AMERICAS
5.1 Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2020-2025)
5.2 Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2020-2025)
5.3 Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region (2020-2025)
6.2 APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2020-2025)
6.3 APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2020-2025)
7.2 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2020-2025)
7.3 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC by Region (2020-2025)
8.2 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2020-2025)
8.3 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL TARGETED DRUG VEGF INHIBITORS FOR NSCLC MARKET FORECAST
10.1 Global Targeted Drug VEGF Inhibitors for NSCLC Forecast by Region (2026-2031)
10.1.1 Global Targeted Drug VEGF Inhibitors for NSCLC Forecast by Region (2026-2031)
10.1.2 Americas Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.1.3 APAC Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.1.4 Europe Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.1.5 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.2 Americas Targeted Drug VEGF Inhibitors for NSCLC Forecast by Country (2026-2031)
10.2.1 United States Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.2.2 Canada Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.2.3 Mexico Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.2.4 Brazil Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.3 APAC Targeted Drug VEGF Inhibitors for NSCLC Forecast by Region (2026-2031)
10.3.1 China Targeted Drug VEGF Inhibitors for NSCLC Market Forecast
10.3.2 Japan Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.3.3 Korea Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.3.4 Southeast Asia Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.3.5 India Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.3.6 Australia Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.4 Europe Targeted Drug VEGF Inhibitors for NSCLC Forecast by Country (2026-2031)
10.4.1 Germany Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.4.2 France Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.4.3 UK Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.4.4 Italy Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.4.5 Russia Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.5 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Forecast by Region (2026-2031)
10.5.1 Egypt Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.5.2 South Africa Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.5.3 Israel Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.5.4 Turkey Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.6 Global Targeted Drug VEGF Inhibitors for NSCLC Forecast by Type (2026-2031)
10.7 Global Targeted Drug VEGF Inhibitors for NSCLC Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
11 KEY PLAYERS ANALYSIS
11.1 Roche
11.1.1 Roche Company Information
11.1.2 Roche Targeted Drug VEGF Inhibitors for NSCLC Product Offered
11.1.3 Roche Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Roche Main Business Overview
11.1.5 Roche Latest Developments
11.2 Pfizer
11.2.1 Pfizer Company Information
11.2.2 Pfizer Targeted Drug VEGF Inhibitors for NSCLC Product Offered
11.2.3 Pfizer Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Pfizer Main Business Overview
11.2.5 Pfizer Latest Developments
11.3 Allergan
11.3.1 Allergan Company Information
11.3.2 Allergan Targeted Drug VEGF Inhibitors for NSCLC Product Offered
11.3.3 Allergan Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Allergan Main Business Overview
11.3.5 Allergan Latest Developments
11.4 Amgen
11.4.1 Amgen Company Information
11.4.2 Amgen Targeted Drug VEGF Inhibitors for NSCLC Product Offered
11.4.3 Amgen Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Amgen Main Business Overview
11.4.5 Amgen Latest Developments
11.5 Biocon
11.5.1 Biocon Company Information
11.5.2 Biocon Targeted Drug VEGF Inhibitors for NSCLC Product Offered
11.5.3 Biocon Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Biocon Main Business Overview
11.5.5 Biocon Latest Developments
11.6 Reliance Lifesciences
11.6.1 Reliance Lifesciences Company Information
11.6.2 Reliance Lifesciences Targeted Drug VEGF Inhibitors for NSCLC Product Offered
11.6.3 Reliance Lifesciences Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Reliance Lifesciences Main Business Overview
11.6.5 Reliance Lifesciences Latest Developments
11.7 Beaconpharma
11.7.1 Beaconpharma Company Information
11.7.2 Beaconpharma Targeted Drug VEGF Inhibitors for NSCLC Product Offered
11.7.3 Beaconpharma Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 Beaconpharma Main Business Overview
11.7.5 Beaconpharma Latest Developments
11.8 Celgene Corporation
11.8.1 Celgene Corporation Company Information
11.8.2 Celgene Corporation Targeted Drug VEGF Inhibitors for NSCLC Product Offered
11.8.3 Celgene Corporation Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 Celgene Corporation Main Business Overview
11.8.5 Celgene Corporation Latest Developments
11.9 Fujifilm Kyowa Kirin Biologics
11.9.1 Fujifilm Kyowa Kirin Biologics Company Information
11.9.2 Fujifilm Kyowa Kirin Biologics Targeted Drug VEGF Inhibitors for NSCLC Product Offered
11.9.3 Fujifilm Kyowa Kirin Biologics Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 Fujifilm Kyowa Kirin Biologics Main Business Overview
11.9.5 Fujifilm Kyowa Kirin Biologics Latest Developments
11.10 Hetero Drugs
11.10.1 Hetero Drugs Company Information
11.10.2 Hetero Drugs Targeted Drug VEGF Inhibitors for NSCLC Product Offered
11.10.3 Hetero Drugs Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.10.4 Hetero Drugs Main Business Overview
11.10.5 Hetero Drugs Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size (2020-2031)
2.1.2 Targeted Drug VEGF Inhibitors for NSCLC Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Targeted Drug VEGF Inhibitors for NSCLC by Country/Region (2020, 2024 & 2031)
2.2 Targeted Drug VEGF Inhibitors for NSCLC Segment by Type
2.2.1 Bevacizumab
2.2.2 Others
2.3 Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type
2.3.1 Targeted Drug VEGF Inhibitors for NSCLC Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
2.4 Targeted Drug VEGF Inhibitors for NSCLC Segment by Application
2.4.1 Squamous Cell Carcinoma of NSCLC
2.4.2 Adenocarcinoma of NSCLC
2.4.3 Large Cell Carcinoma of NSCLC
2.5 Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application
2.5.1 Targeted Drug VEGF Inhibitors for NSCLC Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
3 TARGETED DRUG VEGF INHIBITORS FOR NSCLC MARKET SIZE BY PLAYER
3.1 Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Player
3.1.1 Global Targeted Drug VEGF Inhibitors for NSCLC Revenue by Player (2020-2025)
3.1.2 Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Player (2020-2025)
3.2 Global Targeted Drug VEGF Inhibitors for NSCLC Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 TARGETED DRUG VEGF INHIBITORS FOR NSCLC BY REGION
4.1 Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region (2020-2025)
4.2 Global Targeted Drug VEGF Inhibitors for NSCLC Annual Revenue by Country/Region (2020-2025)
4.3 Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth (2020-2025)
4.4 APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth (2020-2025)
4.5 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth (2020-2025)
4.6 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth (2020-2025)
5 AMERICAS
5.1 Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2020-2025)
5.2 Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2020-2025)
5.3 Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region (2020-2025)
6.2 APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2020-2025)
6.3 APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2020-2025)
7.2 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2020-2025)
7.3 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC by Region (2020-2025)
8.2 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2020-2025)
8.3 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL TARGETED DRUG VEGF INHIBITORS FOR NSCLC MARKET FORECAST
10.1 Global Targeted Drug VEGF Inhibitors for NSCLC Forecast by Region (2026-2031)
10.1.1 Global Targeted Drug VEGF Inhibitors for NSCLC Forecast by Region (2026-2031)
10.1.2 Americas Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.1.3 APAC Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.1.4 Europe Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.1.5 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.2 Americas Targeted Drug VEGF Inhibitors for NSCLC Forecast by Country (2026-2031)
10.2.1 United States Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.2.2 Canada Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.2.3 Mexico Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.2.4 Brazil Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.3 APAC Targeted Drug VEGF Inhibitors for NSCLC Forecast by Region (2026-2031)
10.3.1 China Targeted Drug VEGF Inhibitors for NSCLC Market Forecast
10.3.2 Japan Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.3.3 Korea Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.3.4 Southeast Asia Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.3.5 India Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.3.6 Australia Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.4 Europe Targeted Drug VEGF Inhibitors for NSCLC Forecast by Country (2026-2031)
10.4.1 Germany Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.4.2 France Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.4.3 UK Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.4.4 Italy Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.4.5 Russia Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.5 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Forecast by Region (2026-2031)
10.5.1 Egypt Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.5.2 South Africa Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.5.3 Israel Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.5.4 Turkey Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
10.6 Global Targeted Drug VEGF Inhibitors for NSCLC Forecast by Type (2026-2031)
10.7 Global Targeted Drug VEGF Inhibitors for NSCLC Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Targeted Drug VEGF Inhibitors for NSCLC Forecast
11 KEY PLAYERS ANALYSIS
11.1 Roche
11.1.1 Roche Company Information
11.1.2 Roche Targeted Drug VEGF Inhibitors for NSCLC Product Offered
11.1.3 Roche Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Roche Main Business Overview
11.1.5 Roche Latest Developments
11.2 Pfizer
11.2.1 Pfizer Company Information
11.2.2 Pfizer Targeted Drug VEGF Inhibitors for NSCLC Product Offered
11.2.3 Pfizer Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Pfizer Main Business Overview
11.2.5 Pfizer Latest Developments
11.3 Allergan
11.3.1 Allergan Company Information
11.3.2 Allergan Targeted Drug VEGF Inhibitors for NSCLC Product Offered
11.3.3 Allergan Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Allergan Main Business Overview
11.3.5 Allergan Latest Developments
11.4 Amgen
11.4.1 Amgen Company Information
11.4.2 Amgen Targeted Drug VEGF Inhibitors for NSCLC Product Offered
11.4.3 Amgen Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Amgen Main Business Overview
11.4.5 Amgen Latest Developments
11.5 Biocon
11.5.1 Biocon Company Information
11.5.2 Biocon Targeted Drug VEGF Inhibitors for NSCLC Product Offered
11.5.3 Biocon Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Biocon Main Business Overview
11.5.5 Biocon Latest Developments
11.6 Reliance Lifesciences
11.6.1 Reliance Lifesciences Company Information
11.6.2 Reliance Lifesciences Targeted Drug VEGF Inhibitors for NSCLC Product Offered
11.6.3 Reliance Lifesciences Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Reliance Lifesciences Main Business Overview
11.6.5 Reliance Lifesciences Latest Developments
11.7 Beaconpharma
11.7.1 Beaconpharma Company Information
11.7.2 Beaconpharma Targeted Drug VEGF Inhibitors for NSCLC Product Offered
11.7.3 Beaconpharma Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 Beaconpharma Main Business Overview
11.7.5 Beaconpharma Latest Developments
11.8 Celgene Corporation
11.8.1 Celgene Corporation Company Information
11.8.2 Celgene Corporation Targeted Drug VEGF Inhibitors for NSCLC Product Offered
11.8.3 Celgene Corporation Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 Celgene Corporation Main Business Overview
11.8.5 Celgene Corporation Latest Developments
11.9 Fujifilm Kyowa Kirin Biologics
11.9.1 Fujifilm Kyowa Kirin Biologics Company Information
11.9.2 Fujifilm Kyowa Kirin Biologics Targeted Drug VEGF Inhibitors for NSCLC Product Offered
11.9.3 Fujifilm Kyowa Kirin Biologics Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 Fujifilm Kyowa Kirin Biologics Main Business Overview
11.9.5 Fujifilm Kyowa Kirin Biologics Latest Developments
11.10 Hetero Drugs
11.10.1 Hetero Drugs Company Information
11.10.2 Hetero Drugs Targeted Drug VEGF Inhibitors for NSCLC Product Offered
11.10.3 Hetero Drugs Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.10.4 Hetero Drugs Main Business Overview
11.10.5 Hetero Drugs Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Targeted Drug VEGF Inhibitors for NSCLC Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Targeted Drug VEGF Inhibitors for NSCLC Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Bevacizumab
Table 4. Major Players of Others
Table 5. Targeted Drug VEGF Inhibitors for NSCLC Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 6. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 7. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Table 8. Targeted Drug VEGF Inhibitors for NSCLC Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 9. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 10. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Table 11. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue by Player (2020-2025) & ($ millions)
Table 12. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Player (2020-2025)
Table 13. Targeted Drug VEGF Inhibitors for NSCLC Key Players Head office and Products Offered
Table 14. Targeted Drug VEGF Inhibitors for NSCLC Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region (2020-2025) & ($ millions)
Table 18. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Region (2020-2025)
Table 19. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue by Country/Region (2020-2025) & ($ millions)
Table 20. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Country/Region (2020-2025)
Table 21. Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2020-2025) & ($ millions)
Table 22. Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Country (2020-2025)
Table 23. Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 24. Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Table 25. Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 26. Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Table 27. APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region (2020-2025) & ($ millions)
Table 28. APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Region (2020-2025)
Table 29. APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 30. APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 31. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2020-2025) & ($ millions)
Table 32. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Country (2020-2025)
Table 33. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 34. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 35. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region (2020-2025) & ($ millions)
Table 36. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 37. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of Targeted Drug VEGF Inhibitors for NSCLC
Table 39. Key Market Challenges & Risks of Targeted Drug VEGF Inhibitors for NSCLC
Table 40. Key Industry Trends of Targeted Drug VEGF Inhibitors for NSCLC
Table 41. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Forecast by Region (2026-2031) & ($ millions)
Table 42. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share Forecast by Region (2026-2031)
Table 43. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Forecast by Type (2026-2031) & ($ millions)
Table 44. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Forecast by Application (2026-2031) & ($ millions)
Table 45. Roche Details, Company Type, Targeted Drug VEGF Inhibitors for NSCLC Area Served and Its Competitors
Table 46. Roche Targeted Drug VEGF Inhibitors for NSCLC Product Offered
Table 47. Roche Targeted Drug VEGF Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 48. Roche Main Business
Table 49. Roche Latest Developments
Table 50. Pfizer Details, Company Type, Targeted Drug VEGF Inhibitors for NSCLC Area Served and Its Competitors
Table 51. Pfizer Targeted Drug VEGF Inhibitors for NSCLC Product Offered
Table 52. Pfizer Targeted Drug VEGF Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 53. Pfizer Main Business
Table 54. Pfizer Latest Developments
Table 55. Allergan Details, Company Type, Targeted Drug VEGF Inhibitors for NSCLC Area Served and Its Competitors
Table 56. Allergan Targeted Drug VEGF Inhibitors for NSCLC Product Offered
Table 57. Allergan Targeted Drug VEGF Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 58. Allergan Main Business
Table 59. Allergan Latest Developments
Table 60. Amgen Details, Company Type, Targeted Drug VEGF Inhibitors for NSCLC Area Served and Its Competitors
Table 61. Amgen Targeted Drug VEGF Inhibitors for NSCLC Product Offered
Table 62. Amgen Targeted Drug VEGF Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 63. Amgen Main Business
Table 64. Amgen Latest Developments
Table 65. Biocon Details, Company Type, Targeted Drug VEGF Inhibitors for NSCLC Area Served and Its Competitors
Table 66. Biocon Targeted Drug VEGF Inhibitors for NSCLC Product Offered
Table 67. Biocon Targeted Drug VEGF Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 68. Biocon Main Business
Table 69. Biocon Latest Developments
Table 70. Reliance Lifesciences Details, Company Type, Targeted Drug VEGF Inhibitors for NSCLC Area Served and Its Competitors
Table 71. Reliance Lifesciences Targeted Drug VEGF Inhibitors for NSCLC Product Offered
Table 72. Reliance Lifesciences Targeted Drug VEGF Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 73. Reliance Lifesciences Main Business
Table 74. Reliance Lifesciences Latest Developments
Table 75. Beaconpharma Details, Company Type, Targeted Drug VEGF Inhibitors for NSCLC Area Served and Its Competitors
Table 76. Beaconpharma Targeted Drug VEGF Inhibitors for NSCLC Product Offered
Table 77. Beaconpharma Targeted Drug VEGF Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 78. Beaconpharma Main Business
Table 79. Beaconpharma Latest Developments
Table 80. Celgene Corporation Details, Company Type, Targeted Drug VEGF Inhibitors for NSCLC Area Served and Its Competitors
Table 81. Celgene Corporation Targeted Drug VEGF Inhibitors for NSCLC Product Offered
Table 82. Celgene Corporation Targeted Drug VEGF Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 83. Celgene Corporation Main Business
Table 84. Celgene Corporation Latest Developments
Table 85. Fujifilm Kyowa Kirin Biologics Details, Company Type, Targeted Drug VEGF Inhibitors for NSCLC Area Served and Its Competitors
Table 86. Fujifilm Kyowa Kirin Biologics Targeted Drug VEGF Inhibitors for NSCLC Product Offered
Table 87. Fujifilm Kyowa Kirin Biologics Targeted Drug VEGF Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 88. Fujifilm Kyowa Kirin Biologics Main Business
Table 89. Fujifilm Kyowa Kirin Biologics Latest Developments
Table 90. Hetero Drugs Details, Company Type, Targeted Drug VEGF Inhibitors for NSCLC Area Served and Its Competitors
Table 91. Hetero Drugs Targeted Drug VEGF Inhibitors for NSCLC Product Offered
Table 92. Hetero Drugs Targeted Drug VEGF Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 93. Hetero Drugs Main Business
Table 94. Hetero Drugs Latest Developments
Table 1. Targeted Drug VEGF Inhibitors for NSCLC Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Targeted Drug VEGF Inhibitors for NSCLC Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Bevacizumab
Table 4. Major Players of Others
Table 5. Targeted Drug VEGF Inhibitors for NSCLC Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 6. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 7. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Table 8. Targeted Drug VEGF Inhibitors for NSCLC Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 9. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 10. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Table 11. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue by Player (2020-2025) & ($ millions)
Table 12. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Player (2020-2025)
Table 13. Targeted Drug VEGF Inhibitors for NSCLC Key Players Head office and Products Offered
Table 14. Targeted Drug VEGF Inhibitors for NSCLC Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region (2020-2025) & ($ millions)
Table 18. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Region (2020-2025)
Table 19. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue by Country/Region (2020-2025) & ($ millions)
Table 20. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Country/Region (2020-2025)
Table 21. Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2020-2025) & ($ millions)
Table 22. Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Country (2020-2025)
Table 23. Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 24. Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Table 25. Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 26. Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Table 27. APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region (2020-2025) & ($ millions)
Table 28. APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Region (2020-2025)
Table 29. APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 30. APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 31. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2020-2025) & ($ millions)
Table 32. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Country (2020-2025)
Table 33. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 34. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 35. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region (2020-2025) & ($ millions)
Table 36. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 37. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of Targeted Drug VEGF Inhibitors for NSCLC
Table 39. Key Market Challenges & Risks of Targeted Drug VEGF Inhibitors for NSCLC
Table 40. Key Industry Trends of Targeted Drug VEGF Inhibitors for NSCLC
Table 41. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Forecast by Region (2026-2031) & ($ millions)
Table 42. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share Forecast by Region (2026-2031)
Table 43. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Forecast by Type (2026-2031) & ($ millions)
Table 44. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Forecast by Application (2026-2031) & ($ millions)
Table 45. Roche Details, Company Type, Targeted Drug VEGF Inhibitors for NSCLC Area Served and Its Competitors
Table 46. Roche Targeted Drug VEGF Inhibitors for NSCLC Product Offered
Table 47. Roche Targeted Drug VEGF Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 48. Roche Main Business
Table 49. Roche Latest Developments
Table 50. Pfizer Details, Company Type, Targeted Drug VEGF Inhibitors for NSCLC Area Served and Its Competitors
Table 51. Pfizer Targeted Drug VEGF Inhibitors for NSCLC Product Offered
Table 52. Pfizer Targeted Drug VEGF Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 53. Pfizer Main Business
Table 54. Pfizer Latest Developments
Table 55. Allergan Details, Company Type, Targeted Drug VEGF Inhibitors for NSCLC Area Served and Its Competitors
Table 56. Allergan Targeted Drug VEGF Inhibitors for NSCLC Product Offered
Table 57. Allergan Targeted Drug VEGF Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 58. Allergan Main Business
Table 59. Allergan Latest Developments
Table 60. Amgen Details, Company Type, Targeted Drug VEGF Inhibitors for NSCLC Area Served and Its Competitors
Table 61. Amgen Targeted Drug VEGF Inhibitors for NSCLC Product Offered
Table 62. Amgen Targeted Drug VEGF Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 63. Amgen Main Business
Table 64. Amgen Latest Developments
Table 65. Biocon Details, Company Type, Targeted Drug VEGF Inhibitors for NSCLC Area Served and Its Competitors
Table 66. Biocon Targeted Drug VEGF Inhibitors for NSCLC Product Offered
Table 67. Biocon Targeted Drug VEGF Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 68. Biocon Main Business
Table 69. Biocon Latest Developments
Table 70. Reliance Lifesciences Details, Company Type, Targeted Drug VEGF Inhibitors for NSCLC Area Served and Its Competitors
Table 71. Reliance Lifesciences Targeted Drug VEGF Inhibitors for NSCLC Product Offered
Table 72. Reliance Lifesciences Targeted Drug VEGF Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 73. Reliance Lifesciences Main Business
Table 74. Reliance Lifesciences Latest Developments
Table 75. Beaconpharma Details, Company Type, Targeted Drug VEGF Inhibitors for NSCLC Area Served and Its Competitors
Table 76. Beaconpharma Targeted Drug VEGF Inhibitors for NSCLC Product Offered
Table 77. Beaconpharma Targeted Drug VEGF Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 78. Beaconpharma Main Business
Table 79. Beaconpharma Latest Developments
Table 80. Celgene Corporation Details, Company Type, Targeted Drug VEGF Inhibitors for NSCLC Area Served and Its Competitors
Table 81. Celgene Corporation Targeted Drug VEGF Inhibitors for NSCLC Product Offered
Table 82. Celgene Corporation Targeted Drug VEGF Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 83. Celgene Corporation Main Business
Table 84. Celgene Corporation Latest Developments
Table 85. Fujifilm Kyowa Kirin Biologics Details, Company Type, Targeted Drug VEGF Inhibitors for NSCLC Area Served and Its Competitors
Table 86. Fujifilm Kyowa Kirin Biologics Targeted Drug VEGF Inhibitors for NSCLC Product Offered
Table 87. Fujifilm Kyowa Kirin Biologics Targeted Drug VEGF Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 88. Fujifilm Kyowa Kirin Biologics Main Business
Table 89. Fujifilm Kyowa Kirin Biologics Latest Developments
Table 90. Hetero Drugs Details, Company Type, Targeted Drug VEGF Inhibitors for NSCLC Area Served and Its Competitors
Table 91. Hetero Drugs Targeted Drug VEGF Inhibitors for NSCLC Product Offered
Table 92. Hetero Drugs Targeted Drug VEGF Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 93. Hetero Drugs Main Business
Table 94. Hetero Drugs Latest Developments
LIST OF FIGURES
Figure 1. Targeted Drug VEGF Inhibitors for NSCLC Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Targeted Drug VEGF Inhibitors for NSCLC Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Targeted Drug VEGF Inhibitors for NSCLC Sales Market Share by Country/Region (2024)
Figure 8. Targeted Drug VEGF Inhibitors for NSCLC Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Type in 2024
Figure 10. Targeted Drug VEGF Inhibitors for NSCLC in Squamous Cell Carcinoma of NSCLC
Figure 11. Global Targeted Drug VEGF Inhibitors for NSCLC Market: Squamous Cell Carcinoma of NSCLC (2020-2025) & ($ millions)
Figure 12. Targeted Drug VEGF Inhibitors for NSCLC in Adenocarcinoma of NSCLC
Figure 13. Global Targeted Drug VEGF Inhibitors for NSCLC Market: Adenocarcinoma of NSCLC (2020-2025) & ($ millions)
Figure 14. Targeted Drug VEGF Inhibitors for NSCLC in Large Cell Carcinoma of NSCLC
Figure 15. Global Targeted Drug VEGF Inhibitors for NSCLC Market: Large Cell Carcinoma of NSCLC (2020-2025) & ($ millions)
Figure 16. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Application in 2024
Figure 17. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Player in 2024
Figure 18. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Region (2020-2025)
Figure 19. Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size 2020-2025 ($ millions)
Figure 20. APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size 2020-2025 ($ millions)
Figure 21. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size 2020-2025 ($ millions)
Figure 22. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size 2020-2025 ($ millions)
Figure 23. Americas Targeted Drug VEGF Inhibitors for NSCLC Value Market Share by Country in 2024
Figure 24. United States Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 25. Canada Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 26. Mexico Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 27. Brazil Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 28. APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Region in 2024
Figure 29. APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Figure 30. APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Figure 31. China Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 32. Japan Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 33. South Korea Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 34. Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 35. India Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 36. Australia Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 37. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Country in 2024
Figure 38. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Figure 39. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Figure 40. Germany Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 41. France Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 42. UK Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 43. Italy Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 44. Russia Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 45. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Region (2020-2025)
Figure 46. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Figure 47. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Figure 48. Egypt Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 49. South Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 50. Israel Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 51. Turkey Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 52. GCC Countries Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 53. Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 54. APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 55. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 56. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 57. United States Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 58. Canada Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 59. Mexico Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 60. Brazil Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 61. China Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 62. Japan Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 63. Korea Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 64. Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 65. India Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 66. Australia Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 67. Germany Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 68. France Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 69. UK Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 70. Italy Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 71. Russia Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 72. Egypt Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 73. South Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 74. Israel Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 75. Turkey Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 76. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share Forecast by Type (2026-2031)
Figure 77. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share Forecast by Application (2026-2031)
Figure 78. GCC Countries Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 1. Targeted Drug VEGF Inhibitors for NSCLC Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Targeted Drug VEGF Inhibitors for NSCLC Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Targeted Drug VEGF Inhibitors for NSCLC Sales Market Share by Country/Region (2024)
Figure 8. Targeted Drug VEGF Inhibitors for NSCLC Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Type in 2024
Figure 10. Targeted Drug VEGF Inhibitors for NSCLC in Squamous Cell Carcinoma of NSCLC
Figure 11. Global Targeted Drug VEGF Inhibitors for NSCLC Market: Squamous Cell Carcinoma of NSCLC (2020-2025) & ($ millions)
Figure 12. Targeted Drug VEGF Inhibitors for NSCLC in Adenocarcinoma of NSCLC
Figure 13. Global Targeted Drug VEGF Inhibitors for NSCLC Market: Adenocarcinoma of NSCLC (2020-2025) & ($ millions)
Figure 14. Targeted Drug VEGF Inhibitors for NSCLC in Large Cell Carcinoma of NSCLC
Figure 15. Global Targeted Drug VEGF Inhibitors for NSCLC Market: Large Cell Carcinoma of NSCLC (2020-2025) & ($ millions)
Figure 16. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Application in 2024
Figure 17. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Player in 2024
Figure 18. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Region (2020-2025)
Figure 19. Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size 2020-2025 ($ millions)
Figure 20. APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size 2020-2025 ($ millions)
Figure 21. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size 2020-2025 ($ millions)
Figure 22. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size 2020-2025 ($ millions)
Figure 23. Americas Targeted Drug VEGF Inhibitors for NSCLC Value Market Share by Country in 2024
Figure 24. United States Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 25. Canada Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 26. Mexico Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 27. Brazil Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 28. APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Region in 2024
Figure 29. APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Figure 30. APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Figure 31. China Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 32. Japan Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 33. South Korea Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 34. Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 35. India Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 36. Australia Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 37. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Country in 2024
Figure 38. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Figure 39. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Figure 40. Germany Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 41. France Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 42. UK Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 43. Italy Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 44. Russia Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 45. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Region (2020-2025)
Figure 46. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Figure 47. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Figure 48. Egypt Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 49. South Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 50. Israel Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 51. Turkey Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 52. GCC Countries Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 53. Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 54. APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 55. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 56. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 57. United States Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 58. Canada Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 59. Mexico Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 60. Brazil Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 61. China Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 62. Japan Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 63. Korea Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 64. Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 65. India Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 66. Australia Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 67. Germany Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 68. France Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 69. UK Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 70. Italy Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 71. Russia Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 72. Egypt Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 73. South Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 74. Israel Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 75. Turkey Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 76. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share Forecast by Type (2026-2031)
Figure 77. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share Forecast by Application (2026-2031)
Figure 78. GCC Countries Targeted Drug VEGF Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
More Publications
Global Targeted Drug ALK Inhibitors for NSCLC Market Growth (Status and Outlook) 2025-2031
US$ 3,660.00
September 2025
98 pages
Global Targeted Drug HER2 Inhibitors for NSCLC Market Growth (Status and Outlook) 2025-2031
US$ 3,660.00
September 2025
78 pages
Global Targeted Drug ROS1 Inhibitors for NSCLC Market Growth (Status and Outlook) 2025-2031
US$ 3,660.00
September 2025
70 pages
Global Targeted Drug BRAF Inhibitors for NSCLC Market Growth (Status and Outlook) 2025-2031
US$ 3,660.00
September 2025
74 pages
Global Targeted Drug MEK Inhibitors for NSCLC Market Growth (Status and Outlook) 2025-2031
US$ 3,660.00
September 2025
76 pages
